Tirzepatide
Dual GLP-1/GIP agonist for weight loss
Overview
Tirzepatide is a dual incretin receptor agonist targeting both GLP-1 and GIP receptors. It has demonstrated the highest weight loss efficacy of any approved medication, with some patients losing over 20% of body weight.
Mechanism of Action
Dual agonism of GLP-1 and GIP receptors → enhanced insulin secretion → greater appetite suppression than single agonists → improved lipid metabolism → synergistic incretin effects.
Benefits
- Up to 22.5% weight loss
- Superior to semaglutide in trials
- Improved insulin sensitivity
- Better lipid profiles
- Once-weekly dosing
Dosing Protocol
Half-Life
~5 days
Duration of pharmacological activity after administration.
Side Effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Injection site reactions
- Pancreatitis (rare)
Stacking Recommendations
Storage & Reconstitution
Refrigerate at 2–8°C. In-use pen: room temperature up to 21 days.
Research Notes
FDA-approved as Mounjaro (T2DM) and Zepbound (obesity). SURMOUNT trials showed unprecedented 22.5% weight loss. SURPASS trials proved superiority over semaglutide for diabetes.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.